- 2026 IPO class blooms again as BlossomHill, Latigo set sights on NasdaqEighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the pandemic-driven high of 2021.BioSpace · 7d ago↗ source
- [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services<p>This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.</p>BioPharma Dive · 7d ago↗ source
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…